Imunon, Inc. Forecasted to Post FY2028 Earnings of ($0.32) Per Share (NASDAQ:IMNN)

Imunon, Inc. (NASDAQ:IMNNFree Report) – Research analysts at HC Wainwright issued their FY2028 earnings per share (EPS) estimates for shares of Imunon in a note issued to investors on Monday, April 1st. HC Wainwright analyst E. Bodnar anticipates that the company will earn ($0.32) per share for the year. HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Imunon’s current full-year earnings is ($1.95) per share.

Imunon Stock Up 17.7 %

Shares of NASDAQ:IMNN opened at $1.93 on Tuesday. The business has a fifty day moving average of $0.79 and a two-hundred day moving average of $0.86. The stock has a market cap of $18.14 million, a P/E ratio of -0.89 and a beta of 2.02. Imunon has a 52-week low of $0.48 and a 52-week high of $2.00.

Institutional Trading of Imunon

Several large investors have recently added to or reduced their stakes in IMNN. BlackRock Inc. purchased a new position in shares of Imunon during the 1st quarter worth $83,000. Renaissance Technologies LLC purchased a new position in shares of Imunon during the 1st quarter worth $76,000. Finally, Geode Capital Management LLC purchased a new position in shares of Imunon during the 1st quarter worth $62,000. 4.47% of the stock is currently owned by hedge funds and other institutional investors.

About Imunon

(Get Free Report)

Imunon, Inc, a clinical stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The Company's lead clinical programs comprise IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development; and ThermoDox for the treatment of hepatocellular carcinoma.

Featured Stories

Earnings History and Estimates for Imunon (NASDAQ:IMNN)

Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.